Reversibility of calcinosis in anti-NXP2-positive refractory dermatomyositis treated with TNF-α blockade: a brief report
By
Hui Huang
Haiguo Yu
Zhidan Fan
Yihong Guo
Huihui Ma
Na Huang
Le Ma
May 7, 2026
Clinical Scorecard: Resolution of Calcinosis in Patients with Anti-NXP2-Positive Refractory Dermatomyositis Following TNF-α Inhibition: A Brief Report
At a Glance
Category Detail
Condition Key Mechanisms Target Population Patients with refractory dermatomyositis, particularly those with anti-NXP2 autoantibodies, aged 7.8 years on average. Care Setting
Key Highlights
TNF-α antagonists linked to significant steroid-sparing effect and improved quality of life. Radiographic improvement of calcinosis observed in 2 of 3 anti-NXP2-positive individuals, indicating potential treatment efficacy. Calcinosis absent at baseline in all anti-NXP2-negative individuals, highlighting the need for targeted therapies. Study suggests antibody-defined subgroups may respond differently to treatment, necessitating personalized approaches. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Assess muscle strength and glucocorticoid dosage regularly, ideally every 3 months. Risks
Patient & Prescribing Data
Nine individuals with refractory dermatomyositis, median age 7.8 years.
Median daily prednisolone dosage decreased from 40 mg to 5 mg over 12 months.
Clinical Best Practices
Utilize serial radiography to assess calcinosis and involve rheumatology, dermatology, and rehabilitation specialists for comprehensive management. Related Resources & Content
